A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
Clinical trial NCT07309419 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07309419
- Sponsor
- Shanghai Zhongshan Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-22
- Primary completion
- 2030-06-30
- Enrollment
- 222
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.